Dosage forms of mirdametinib
US12383517B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2024 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Oct 10, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.